Patient Selection Approaches in FGFR Inhibitor Trials-Many Paths to the Same End?

P Ellinghaus; Daniel Neureiter; H Nogai; S Stintzing; M Ocker

doi:10.3390/cells11193180

Patient Selection Approaches in FGFR Inhibitor Trials-Many Paths to the Same End?

P Ellinghaus, Daniel Neureiter (Co-author), H Nogai, S Stintzing, M Ocker

Institute of Pathology

Research output: Contribution to journal › Review article › peer-review

11 Citations (Web of Science)

Original language	English
Pages (from-to)	3180
Journal	CELLS
Volume	11
Issue number	19
DOIs	https://doi.org/10.3390/cells11193180
Publication status	Published - 2022

Keywords

FIBROBLAST-GROWTH-FACTOR
CELL LUNG-CANCER
FACTOR RECEPTOR INHIBITOR
GENE COPY NUMBER
ANTITUMOR-ACTIVITY
HEPATOCELLULAR-CARCINOMA
PROTEIN OVEREXPRESSION
ACQUIRED-RESISTANCE
THERAPEUTIC TARGET
EXPRESSION LEVELS

Access to Document

10.3390/cells11193180

Cite this

@article{140343c481104d58bc51c8d3c5564463,

title = "Patient Selection Approaches in FGFR Inhibitor Trials-Many Paths to the Same End?",

keywords = "FIBROBLAST-GROWTH-FACTOR, CELL LUNG-CANCER, FACTOR RECEPTOR INHIBITOR, GENE COPY NUMBER, ANTITUMOR-ACTIVITY, HEPATOCELLULAR-CARCINOMA, PROTEIN OVEREXPRESSION, ACQUIRED-RESISTANCE, THERAPEUTIC TARGET, EXPRESSION LEVELS",

author = "P Ellinghaus and Daniel Neureiter and H Nogai and S Stintzing and M Ocker",

note = "Neureiter, D: Institute of Pathology, University Clinics Salzburg, Paracelsus Medical University, 5020 Salzburg, Austria***Cancer Cluster Salzburg, 5020 Salzburg, Austria ",

year = "2022",

doi = "10.3390/cells11193180",

language = "English",

volume = "11",

pages = "3180",

journal = "CELLS",

issn = "2073-4409",